Oryzon Genomics S.A. (ORY.MC)
EUR 2.66
(1.33%)
EUR 2.66
(1.33%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.06 EUR | 27.02% |
| 2022 | -0.08 EUR | 14.98% |
| 2021 | -0.09 EUR | -37.89% |
| 2020 | -0.06 EUR | 0.0% |
| 2019 | - EUR | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | 0.00 EUR | 111.49% |
| 2024 Q3 | -0.02 EUR | -1190.0% |
| 2024 Q1 | -0.02 USD | 41.02% |
| 2023 Q4 | -0.03 EUR | -61.2% |
| 2023 FY | - EUR | 27.02% |
| 2023 Q3 | -0.02 EUR | -199.46% |
| 2023 Q2 | 0.02 EUR | 163.67% |
| 2023 Q1 | -0.03 EUR | 0.0% |
| 2022 Q4 | - EUR | 0.0% |
| 2022 FY | - EUR | 14.98% |
| 2021 FY | - EUR | -37.89% |
| 2020 FY | - EUR | 0.0% |
| 2019 FY | - EUR | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Atrys Health, S.A. | -0.60 EUR | 90.817% |
| Biotechnologies Assets SA | 0.03 EUR | 301.832% |
| Pharma Mar, S.A. | 0.06 EUR | 186.772% |
| Laboratorios Farmaceuticos Rovi, S.A. | 3.29 EUR | 101.675% |